Shares in Boston biotech resTORbio (Nasdaq: TORC) were worth 86% less by Friday’s close after the announcement of top-line data from the Phase III study on the company’s lead candidate.
RTB101, a TORC1 inhibitor, was being studied in the PROTECTOR 1 study, looking at the prevention of clinically symptomatic respiratory illness (CSRI) in adults aged 65 and older.
"There are extensive preclinical data supporting the potential therapeutic benefit of TORC1 inhibition in multiple aging-related diseases"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze